NO20073901L - Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis - Google Patents

Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis

Info

Publication number
NO20073901L
NO20073901L NO20073901A NO20073901A NO20073901L NO 20073901 L NO20073901 L NO 20073901L NO 20073901 A NO20073901 A NO 20073901A NO 20073901 A NO20073901 A NO 20073901A NO 20073901 L NO20073901 L NO 20073901L
Authority
NO
Norway
Prior art keywords
radiation
mucosistis
cyst
estrogen receptor
selective agonists
Prior art date
Application number
NO20073901A
Other languages
English (en)
Inventor
Heather Anne Harris
William Jacobson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36597596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073901(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20073901L publication Critical patent/NO20073901L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en metode for behandling eller hemning av mucositt eller strålings-cystitt ved anvendelse av en ERP-selektiv ligand. Foreliggende oppfinnelse tilveiebringer også preparater, omfattende farmasøytiske preparater, inneholdende den ERp-selektive ligand og et tradisjonelt medikament for mucositt eller strålings-cystitt.
NO20073901A 2005-02-16 2007-07-25 Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis NO20073901L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65337605P 2005-02-16 2005-02-16
PCT/US2006/005000 WO2006088784A1 (en) 2005-02-16 2006-02-14 Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis

Publications (1)

Publication Number Publication Date
NO20073901L true NO20073901L (no) 2007-11-15

Family

ID=36597596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073901A NO20073901L (no) 2005-02-16 2007-07-25 Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis

Country Status (20)

Country Link
US (1) US20060211672A1 (no)
EP (1) EP1848427A1 (no)
JP (1) JP2008530210A (no)
KR (1) KR20070103456A (no)
CN (1) CN101119721A (no)
AR (1) AR053332A1 (no)
AU (1) AU2006214515A1 (no)
BR (1) BRPI0608154A2 (no)
CA (1) CA2596984A1 (no)
CR (1) CR9263A (no)
GT (1) GT200600064A (no)
IL (1) IL185009A0 (no)
MX (1) MX2007009914A (no)
NI (1) NI200700182A (no)
NO (1) NO20073901L (no)
PE (1) PE20061092A1 (no)
RU (1) RU2007128819A (no)
TW (1) TW200640451A (no)
WO (1) WO2006088784A1 (no)
ZA (1) ZA200706785B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059574A1 (es) * 2006-02-14 2008-04-16 Wyeth Corp Formulaciones farmaceuticas acuosas de ligandos selectivos er-beta
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US20150018398A1 (en) * 2013-07-15 2015-01-15 The Regents Of The University Of California Methods of using estrogen receptor-beta ligands as radiation mitigators
US12346432B2 (en) * 2018-12-31 2025-07-01 Intel Corporation Securing systems employing artificial intelligence

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
AU2207897A (en) * 1996-03-11 1997-10-01 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
BR0108107A (pt) * 2000-01-28 2003-03-11 Endorech Inc Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
EP1609468A3 (en) * 2000-11-22 2006-01-25 Rxkinetix, Inc. A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
PT1997478E (pt) * 2001-02-15 2013-12-10 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc

Also Published As

Publication number Publication date
TW200640451A (en) 2006-12-01
MX2007009914A (es) 2007-09-25
ZA200706785B (en) 2009-08-26
CN101119721A (zh) 2008-02-06
PE20061092A1 (es) 2006-12-05
WO2006088784A1 (en) 2006-08-24
CA2596984A1 (en) 2006-08-24
IL185009A0 (en) 2008-08-07
BRPI0608154A2 (pt) 2016-10-11
AR053332A1 (es) 2007-05-02
CR9263A (es) 2007-11-23
JP2008530210A (ja) 2008-08-07
US20060211672A1 (en) 2006-09-21
NI200700182A (es) 2008-05-13
RU2007128819A (ru) 2009-03-27
KR20070103456A (ko) 2007-10-23
AU2006214515A1 (en) 2006-08-24
EP1848427A1 (en) 2007-10-31
GT200600064A (es) 2006-11-09

Similar Documents

Publication Publication Date Title
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
NO20081160L (no) Benzimidazoltiofen forbindelser
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CL2008001057A1 (es) Agente para el tratamiento de micosis producida por saprolegnia, achlya y/o aphanomyces en peces, el cual comprende al menos un fungicida seleccionado entre a) inhibidores de l a mitosis y division celular, b) inhiidores de la sintesis de ergosterol o, c) derivados de piridina, benzopiranona, carbonitrilo,quinolinas, entre otras.
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
SE0301700D0 (sv) Novel compounds
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
NO20076401L (no) Diarylhydantoinforbindelser
ATE433447T1 (de) Pyrimiidinverbindungen
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
MX2007006204A (es) Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
NO20073901L (no) Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NO341574B1 (no) Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode.
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20075321L (no) Fremgangsmate for bronnbehandling og konstruksjon
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
NO20054535L (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application